<DOC>
	<DOCNO>NCT00389610</DOCNO>
	<brief_summary>RATIONALE : Vaccines make gene-modified tumor cell may help body build immune response kill tumor cell . Giving booster vaccination may make strong immune response prevent delay recurrence pancreatic cancer . PURPOSE : This phase II trial study side effect well vaccine therapy work treat patient pancreatic cancer remove surgery .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Pancreatic Cancer That Has Been Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety primary boost vaccination lethally irradiate allogeneic pancreatic tumor cell transfected sargramostim ( GM-CSF ) gene vaccine patient surgically resect adenocarcinoma head , neck , uncinate pancreas . Secondary - Correlate specific vivo parameter immune response ( e.g. , mesothelin , prostate stem cell antigen , mutate k-ras-specific T-cell response ) clinical response patient treat regimen . - Determine efficacy , term overall recurrence-free survival , regimen patient . - Correlate serum GM-CSF level longevity allogeneic vaccine semi-annual boosting patient . - Determine psychosocial ( e.g. , demographic , quality life , hope , trust , social support , decision control , advanced directive ) symptom ( e.g. , pain , anorexia , fatigue , mood state ) profile patient explore change time . OUTLINE : This open-label study . Patients stratify accord prior vaccination allogeneic sargramostim ( GM-CSF ) -secreting pancreatic tumor cell vaccine ( yes [ stratum I ] vs [ stratum II ] ) . - Stratum I : Patients receive booster vaccination comprise allogeneic GM-CSF plasmid DNA pancreatic tumor cell vaccine subcutaneously ( SC ) . Treatment repeat every 6 month absence disease progression unacceptable toxicity . - Stratum II : Patients receive prim vaccination SC month 3 month receive booster vaccination stratum I . Patients complete self-reported psychosocial ( include quality life , hope , trust ) symptom ( include pain , fatigue , anorexia , mood ) questionnaires day 0 day 28 . After completion study treatment , patient follow day 28 annually 15 year . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis adenocarcinoma head , neck , tail , uncinate pancreas meeting follow criterion : Stage IIII disease Prior surgical resection require No radiographic evidence disease recurrence PATIENT CHARACTERISTICS : ECOG performance status 01 Hemoglobin ≥ 9 g/dL Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 2.0 mg/dL Bilirubin ≤ 2.0 mg/dL ( unless due know Gilbert 's syndrome ) AST , ALT , amylase ≤ 2 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled illness No active , ongoing infection No history autoimmune disease ( e.g. , systemic lupus erythematosus , sarcoidosis , rheumatoid arthritis , glomerulonephritis , vasculitis ) PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 28 day since prior anticancer therapy ( e.g. , adjuvant chemoradiotherapy ) At least 28 day since prior systemic steroid therapy At least 6 month since last vaccination sargramostim ( GMCSF ) plasmid DNA pancreatic tumor cell vaccine ( cell line Panc 10.05 Panc 6.03 ) enrol SKCCCJ9617 SKCCCJ9988 No concurrent systemic steroid therapy ≥ 28 day vaccination No concurrent radiation therapy No concurrent immunotherapy , biologic therapy , gene therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>